Pathalys - About the company
Pathalys is a series B company based in Raleigh (United States), founded in 2021 by Takeshi Takahashi, Mahesh Krishnan, BT Slingsby, Ashwin Ram and Jay Shepard. It operates as a Provider of CKD biotherapeutics development services. Pathalys has raised $105M in funding from Abingworth and TCG Crossover. The company has 138 active competitors, including 14 funded and 15 that have exited. Its top competitors include companies like Ceresti, Aqtual and Evergreen Nephrology.
Company Details
- Website
- pathalys.com
- Social
- Email ID
- *****@pathalys.com
Key Metrics
Founded Year
2021
Location
Raleigh, United States
Stage
Series B
Total Funding
$105M in 2 rounds
Latest Funding Round
Investors
Ranked
7th among 138 active competitors
Sign up to download Pathalys' company profile
Pathalys's funding and investors
Pathalys has raised a total funding of $105M over 2 rounds. Its first funding round was on Jan 19, 2023. Its latest funding round was a Series B round on Aug 20, 2024 for $*****. 8 investors participated in its latest round. Pathalys has 11 institutional investors.
Here is the list of recent funding rounds of Pathalys:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 20, 2024 | 4843754 | Series B | 6801220 | 9798480 | 8934245 | 8801264 |
Jan 19, 2023 | 2789941 | Seed | 1691436 | 7763985 |
Access funding benchmarks and valuations. Sign up today!View details of Pathalys's funding rounds and investors
Pathalys' founders and board of directors
Founder? Claim ProfileThe founders of Pathalys are Takeshi Takahashi, Mahesh Krishnan, BT Slingsby, Ashwin Ram and Jay Shepard. Neal Fowler is the CEO of Pathalys.
Here are the details of Pathalys' key team members:
- Takeshi Takahashi: Co-Founder of Pathalys. Contact Info: 1 email address
- Mahesh Krishnan: Co-Founder of Pathalys. Contact Info: 1 email address
- BT Slingsby: Co-Founder of Pathalys. Contact Info: 1 email address
- Ashwin Ram: Co-Founder of Pathalys. Contact Info: 1 email address
- Jay Shepard: Co-Founder of Pathalys. Contact Info: 1 email address
View details of Pathalys's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Pathalys's Competitors and alternates
Top competitors of Pathalys include Ceresti, Aqtual and Evergreen Nephrology. Here is the list of Top 10 competitors of Pathalys, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Ceresti 2013, Carlsbad (United States), Series B | Provider of chronic care management and monitoring solutions | $36.1M | 49/100 | |
2nd |  Aqtual 2017, San Francisco (United States), Series B | Provider of clinical product launching, chronic disease solution, and diagnostic platform services | $47M | 49/100 | |
3rd |  Evergreen Nephrology 2021, Nashville (United States), Series D | Provider of chronic care management services for kidney diseases | $130M | 43/100 | |
4th |  AdaptX 2016, Seattle (United States), Series A | Provider of clinical management solutions | $24.1M | 42/100 | |
5th |  Tria Health 2009, Overland Park (United States), Unfunded | Provider of chronic care management services | - | - | 38/100 |
6th |  HealthNEXT 2008, Philadelphia (United States), Acquired | Provider of patient management solutions | $200K | 36/100 | |
7th |  Pathalys 2021, Raleigh (United States), Series B | Provider of CKD biotherapeutics development services | $105M | 34/100 | |
8th |  Future Cardia 2021, Houston (United States), Series A | Provider of chronic care management services | $5M | 36/100 | |
9th |  Vivecti Group 2023, Ulm (Germany), Funding Raised | Healthcare performance partner offering patient care management services | - | 35/100 | |
10th |  Brown & Toland 1992, Oakland (United States), Acquired | Provider of healthcare technology and chronic care management services | - | - | 34/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Pathalys's competitors? Click here to see the top ones
Pathalys's Investments and acquisitions
Pathalys has made no investments or acquisitions yet.
Reports related to Pathalys
Here is the latest report on Pathalys's geography:
News related to Pathalys
•
Pathalys Pharma’s $105 Million Series B Financing RoundGlobal Legal Chronicle•Sep 11, 2024•Wilson Sonsini Goodrich & Rosati, J P Morgan, Pathalys
•
Pathalys secures $105m to advance SHPT drug through approvalPharmaceutical Technology•Aug 21, 2024•Pathalys, J P Morgan, Samsara BioCapital, Marshall Wace and 4 others
•
Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDAFierce Biotech•Aug 20, 2024•Pathalys, TCG Crossover, J.P. Morgan Asset Management, Samsara BioCapital and 6 others
•
Pathalys Pharma Raises $105M in Series B FundingFinSMEs•Aug 20, 2024•Pathalys, TCG Crossover, J.P. Morgan Asset Management, Samsara BioCapital and 5 others
•
•
Pathalys Pharma brings in $150M for SHPT trialsLabiotech•Jan 19, 2023•Pathalys, Launch Therapeutics, The Carlyle Group, Abingworth and 4 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Pathalys
Explore our recently published companies
- Kela - 2024 founded, Funding Raised company
- BHI - New York City based, 2026 founded, Unfunded company
- Sherwood Crown Investment - Nottingham based, 2024 founded, Unfunded company
- Roman Tiles - London based, 2019 founded, Unfunded company
- Fox59 - 1996 founded, Unfunded company
- Kfor - 1995 founded, Unfunded company
